Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse ® in treating MuSK Antibody Positive Myasthenia Gravis

Catalyst intends to proceed to U.S. multi-center pivotal trial
Expects additional data to be presented at upcoming medical congresses in 2017
 
CORAL GABLES, Fla., March 15, 2017 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare neuromuscular and neurological diseases, today announced positive top-line results from the investigator-sponsored trial evaluating Firdapse® (Amifampridine Phosphate) as a treatment for myasthenia gravis patients with anti-MuSK antibodies (MuSK-MG).
Read more: Catalyst Pharmaceuticals ( CPRX )

Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results

– Opened two new INDs for wholly-owned SPEAR® T-cell therapies; Company now has four open INDs in 11 indications –
– Received orphan designation, PRIME regulatory support and Breakthrough Therapy designation for NY-ESO SPEAR T-cell –
– Received FDA notification of permission to proceed with new cell manufacturing process –
– Conference call to be held today at 8:00 a.m. EDT (12:00 p.m. GMT) –
 
PHILADELPHIA and OXFORD, United Kingdom, March 13, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2016.
 
“2016 was an important year for Adaptimmune during which we established substantial clinical momentum and significantly advanced our commercial-ready cell manufacturing process,” commented James Noble, Adaptimmune’s Chief Executive Officer.
Read more: Adaptimmune Therapeutics ( ADAP )

Kitov Announces License Agreement for KIT-302 in South Korea

TEL AVIV, Israel, March 8, 2017 -- Definitive agreement grants KuhnilPharmaceutical Co. Ltd.an exclusive license tomanufactureand marketKIT-302 in South Korea 
 
TransactionisKitov's FirstLicenseAgreement for KIT-302 
Celecoxibis the leadingNSAIDproduct in South Koreawithreportedsales of over $55 Million in 2015 
 
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that the Company has signed a definitive License Agreement for its lead product candidate, KIT-302, which was developed to simultaneously treat pain caused by osteoarthritis and to treat hypertension, for the territory of South Korea with Kuhnil Pharmaceutical Co. Ltd., a leading South Korea-based pharmaceutical company.  Upon receipt of marketing authorization in South Korea, Kuhnil will have the exclusive right and license to manufacture, distribute and sell KIT-302 in South Korea.  Kuhnil will be responsible for seeking regulatory approval for KIT-302 in South Korea.
Read more: Kitov Pharmaceuticals Holdings ( KTOV )

Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement

MADISON, Wis., March 08, 2017 -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces it has entered into a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property rights covering the method of use (MOU) for the company’s lead PDC compound, CLR 131, in multiple myeloma.  
 
“We are extremely pleased to further strengthen our relationship with Cellectar,” said Carrie Thome, WARF director of investments.  “WARF’s ability to use the many assets that exist in our portfolio to help advance an important new technology towards ultimate commercialization is a wonderful example of the power of the unique WARF model that combines world class technology transfer and investment management capabilities.”
Read more: Cellectar Biosciences Inc ( CLRB )

Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy

IV OCR-002 statistically significantly normalized ammonia faster than standard of care
Ammonia reduction statistically significantly correlated with clinical improvement in HE symptoms
Ocera plans to meet with FDA in Q3 2017 to inform development paths forward for IV OCR-002
Company presentation scheduled for today, March 8, 2017 at 11:20 AM ET
 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 08, 2017 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced it will report additional encouraging results from its Phase 2b STOP-HE study of intravenous (IV) OCR-002 in hospitalized patients with Hepatic Encephalopathy (HE) at the Cowen and Company 37th Annual Healthcare Conference at 11:20 AM Eastern Time today.
Read more: Ocera Therapeutics Inc ( OCRX )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker